India mandates QR codes for vaccines, cancer drugs to fight counterfeit medicines
Synopsis
India has quietly executed one of its most significant pharmaceutical regulatory moves in years — expanding mandatory QR code traceability from just the top 300 brands to vaccines, cancer drugs, antimicrobials, and narcotic substances. With AMR on the rise and spurious drugs a persistent threat, the amendment to the Drugs Rules, 1945 could reshape accountability across a supply chain that serves over 200 countries.
Key Takeaways
The Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 , mandating QR codes on vaccines, antimicrobials, anti-cancer medicines, and narcotic and psychotropic drugs.
These categories have been brought under Schedule H2 , expanding India's existing pharmaceutical track-and-trace framework.
Previously, QR code requirements applied only to the top 300 pharmaceutical brands in India.
Compliance for vaccines, anti-cancer drugs, and narcotics is required from 1 July 2027 ; for antimicrobials from 1 July 2028 .
The move is also intended to support the fight against Anti-Microbial Resistance (AMR) by curbing counterfeit and substandard antimicrobial products.
The Ministry of Health and Family Welfare (MoHFW) has notified amendments to the Drugs Rules, 1945, making it mandatory for manufacturers of vaccines, antimicrobials, anti-cancer medicines, and narcotic and psychotropic drugs to carry a barcode or QR code on their packaging — a move aimed at curbing counterfeit medicines and strengthening India's pharmaceutical supply chain. The notification was issued on Thursday, 25 June, according to an official government statement.
What the Amendment Covers
Under the revised Drugs Rules, 1945, these drug categories have been brought under Schedule H2, expanding the scope of the existing track-and-trace framework. Manufacturers will be required to print or affix the QR code on the primary packaging label of the product, or on the secondary packaging label where space is insufficient.
The QR code will store and make accessible — through software applications — a range of critical details: the unique product identification code, generic and brand names, name and address of the manufacturer, batch number, manufacturing and expiry dates, manufacturing licence number, and information on excipients wherever applicable.
Why This Matters
Until now, QR code-based identification was mandatory only for the top 300 pharmaceutical brands in India. The expanded mandate significantly widens the traceability net to cover some of the most sensitive and high-risk drug categories in the market.
Notably, the government has explicitly linked this move to the fight against Anti-Microbial Resistance (AMR) — a growing global health crisis. By enabling identification and monitoring of counterfeit and substandard antimicrobial products, the framework is expected to reduce the misuse and circulation of fake antibiotics, which are a key driver of AMR. This is a significant policy signal, as India is among the world's largest consumers of antimicrobials.
Phased Compliance Timeline
To allow manufacturers adequate time to adapt, the government has prescribed a phased rollout. Provisions covering vaccines, anti-cancer medicines, and narcotic and psychotropic drugs under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, will come into force from 1 July 2027. Provisions relating to antimicrobials will become effective from 1 July 2028.
Regulatory and Supply Chain Impact
The enhanced traceability mechanism is designed to enable authentication of medicines at every stage of the supply chain — from manufacturer to distributor to end consumer. The government stated that the measure will improve regulatory oversight, transparency, safety, and accountability across India's pharmaceutical sector.
India's pharmaceutical industry is one of the largest in the world by volume, supplying generics to over 200 countries. The integrity of its domestic supply chain has long been a concern, with spurious and substandard drugs periodically surfacing in government health programmes. This amendment represents one of the most comprehensive traceability expansions in recent years, and its implementation will be closely watched by both domestic regulators and international health agencies.
Point of View
Not notification. India's drug regulatory architecture has historically struggled with last-mile compliance, particularly in tier-2 and tier-3 distribution chains where counterfeit medicines are most likely to enter the market. The AMR link is especially significant: substandard antibiotics are a documented driver of resistance, and traceability without verification infrastructure risks becoming a paper exercise. The phased timeline to 2027–2028 gives industry breathing room, but also means two more years of untracked high-risk drugs in circulation. The MoHFW will need to pair this amendment with investment in digital verification infrastructure and penalties with teeth — otherwise this joins a long line of well-intentioned pharmaceutical regulations that looked stronger on paper than in practice.
NationPress
25 Jun 2026
Frequently Asked Questions
What is the new QR code mandate for medicines in India?
The Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 to make QR codes or barcodes mandatory on the packaging of vaccines, antimicrobials, anti-cancer medicines, and narcotic and psychotropic drugs. The codes will store product details including batch number, manufacturer information, and expiry dates to enable authentication across the supply chain.
Which drug categories are covered under the new amendment?
The amendment covers vaccines, antimicrobials, all anti-cancer medicines, and narcotic and psychotropic drugs listed under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. All these categories have been brought under Schedule H2 of the Drugs Rules, 1945.
When will the QR code mandate come into effect?
Provisions for vaccines, anti-cancer medicines, and narcotic and psychotropic drugs will come into force from 1 July 2027. Provisions for antimicrobials will take effect from 1 July 2028, giving manufacturers additional time to comply.
How is this different from the existing QR code requirement?
Previously, QR code-based identification was mandatory only for the top 300 pharmaceutical brands in India. The new amendment significantly expands this to cover entire high-risk drug categories, irrespective of brand ranking.
How does this help fight Anti-Microbial Resistance (AMR)?
By enabling identification and monitoring of counterfeit and substandard antimicrobial products across the supply chain, the QR code framework is expected to reduce the circulation of fake antibiotics — a key contributor to AMR. India is among the world's largest consumers of antimicrobials, making this a critical regulatory intervention.
